NCT06521931View on ClinicalTrials.gov

A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients

PHASE1RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 6, 2023

Primary Completion Date

December 30, 2024

Study Completion Date

December 30, 2024

Conditions
Thrombocytopenia
Interventions
DRUG

PN20

Three dose cohorts: 0.2, 0.5 and 0.75 mg/kg, subcutaneous injections, on Day 1 of chemotherapy cycle before the administration of chemotherapy drugs

Trial Locations (6)

266057

RECRUITING

The Affiliated Hospital of Qingdao University, Qingdao

413099

RECRUITING

Yiyang Central Hospital, Yiyang

450008

RECRUITING

Henan Cancer Hospital, Zhengzhou

471003

RECRUITING

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang

646000

RECRUITING

Affiliated Hospital of Southwest Medical University, Luzhou

071000

RECRUITING

Affiliated Hospital of Hebei University, Baoding

All Listed Sponsors
lead

Chongqing Peg-Bio Biopharm Co., Ltd.

INDUSTRY